Ospedale S. Eugenio, ASL Roma 2

The research program at Ospedale S. Eugenio focuses on hematologic malignancies and related blood disorders, aiming to test innovative therapies that improve survival and reduce disease burden. Current studies explore how targeted agents and immunotherapies can achieve deeper molecular remission in conditions such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.

• Targeted Bcl‑2 inhibition combined with monoclonal antibodies
• BTK inhibitor addition for resistant disease
• Tyrosine‑kinase inhibitor strategies in Ph+ leukemia
• MRD‑guided treatment adaptation

The site’s multidisciplinary team of five investigators collaborates closely with patients to assess treatment effectiveness and safety, fostering rapid translation of promising results into clinical practice.

In the area of solid and blood‑cell cancers, Ospedale S. Eugenio conducts trials that evaluate novel drug combinations and transplantation approaches for diseases including acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. The primary goal is to determine whether these new regimens can extend overall survival and achieve durable remission, especially in high‑risk patient groups.

• Molecularly targeted agents for NPM1‑mutated AML
• Hypomethylating therapies combined with stem cell transplantation
• Novel monoclonal antibodies to reduce residual disease
• Agents addressing anemia and thrombocytopenia in MDS

By integrating cutting‑edge science with patient‑centered care, the research unit seeks to bring forward safer and more effective options for individuals facing aggressive neoplastic conditions.